Evidence‑Based Diagnostic Workup for Bilateral Lower Extremity Polyneuropathy

Initial High‑Yield Laboratory Screening

• Order blood glucose (or HbA1c), serum vitamin B12 with methylmalonic acid ± homocysteine, and serum protein immunofixation electrophoresis (IFE) as the first‑line tests because they provide the greatest diagnostic yield in patients with EMG‑confirmed bilateral lower‑extremity polyneuropathy. 1
• Diabetes mellitus and pre‑diabetes account for a substantial proportion of polyneuropathy cases; therefore, fasting glucose or HbA1c should be obtained in every patient. 1
• Serum B12 alone can miss deficiency when levels are low‑normal; measuring methylmalonic acid (and optionally homocysteine) improves detection of true B12 deficiency. 1
• IFE is more sensitive than standard SPEP for monoclonal gammopathies, which are present in roughly 10 % of polyneuropathy patients. 1

Secondary Testing Based on Initial Results

• If fasting glucose is normal but the patient has painful sensory symptoms, perform a glucose tolerance test (GTT) because 25‑36 % of idiopathic distal symmetric polyneuropathy patients have impaired glucose tolerance despite normal routine glucose values. 1
• An elevated methylmalonic acid level is highly sensitive (≈ 98 %) and more specific for B12 deficiency than homocysteine (≈ 96 % sensitivity). 1
• Elevated homocysteine may also reflect folate deficiency (≈ 91 % sensitivity), pyridoxine deficiency, renal insufficiency, hypothyroidism, or hypovolemia, and therefore is not specific for B12 deficiency. 1

Genetic Testing Considerations

• Consider genetic testing when the clinical picture suggests a hereditary neuropathy phenotype (slowly progressive course, foot deformities, or family history) even if the family history is unclear. 2
• Prior to testing, classify the neuropathy as primarily demyelinating or axonal based on EMG findings. 2
• An initial hereditary neuropathy panel should include:
  
  • CMT1A duplication / HNPP deletion – the most common hereditary neuropathy. 2
  • GJB1 (Cx32) mutation – for X‑linked forms. 2
  • MFN2 mutation – for axonal forms. 2
• Routine genetic testing is not supported by sufficient evidence in patients lacking a classic hereditary phenotype. 2

Special Diagnostic Testing for Small‑Fiber and Autonomic Neuropathy

• In patients with prominent pain, burning, or autonomic symptoms and normal or minimally abnormal EMG/NCS, obtain a skin biopsy with intraepidermal nerve‑fiber density measurement; this validates small‑fiber loss. 3
• Skin biopsy using PGP 9.5 immunohistochemistry is a validated technique for documenting small‑fiber pathology. 3
• When large‑fiber studies are normal but clinical suspicion for small‑fiber neuropathy remains high, skin biopsy adds diagnostic value. 3
• For suspected autonomic involvement (orthostatic intolerance, abnormal sweating, etc.), perform autonomic testing such as heart‑rate variability with deep breathing, Valsalva maneuver, and quantitative sudomotor axon reflex testing. 3

Diagnostic Pitfalls and Recommendations

• Do not rely on serum B12 levels alone; always include methylmalonic acid ± homocysteine because 44 % of B12‑deficient patients have normal serum B12. 1
• Do not substitute standard SPEP for IFE; IFE detects ≈ 30 % more IgM monoclonal gammopathies, especially low‑level clones. 1
• Do not omit glucose tolerance testing when fasting glucose is normal, particularly in painful sensory polyneuropathy. 1

Additional Targeted Testing Based on Clinical Context

• Tailor further investigations to specific clinical clues (e.g., ANA for suspected vasculitis, heavy‑metal panels for occupational exposure, HIV testing for risk factors). These targeted tests are evidence‑based adjuncts to the core screening algorithm. 1

Diagnostic Approach to Polyneuropathy

Clinical Assessment

• The diagnosis of polyneuropathy should be based upon a combination of clinical symptoms, signs, and electrodiagnostic criteria, with subsequent laboratory testing to identify the underlying etiology, as recommended by the American Academy of Physical Medicine and Rehabilitation 4, 5
• Evaluate for characteristic symptoms of polyneuropathy including distal paresthesias, numbness, pain, cramps, and weakness that typically begin symmetrically in the toes and feet, later progressing to fingertips, according to the American Academy of Neurology 6
• Physical examination should focus on distal muscle weakness and wasting, gait abnormalities, and autonomic signs, as suggested by the American Academy of Physical Medicine and Rehabilitation 6, 7

Electrodiagnostic Studies

• Nerve conduction studies and electromyography are essential to confirm the diagnosis of polyneuropathy, distinguish between axonal and demyelinating patterns, and document the severity and distribution of nerve involvement, as recommended by the American Academy of Physical Medicine and Rehabilitation 5

Laboratory Testing

• Screening laboratory tests should be performed for all patients with confirmed polyneuropathy, including blood glucose, serum B12 with metabolites, serum protein immunofixation electrophoresis, complete blood count, erythrocyte sedimentation rate, comprehensive metabolic panel, and thyroid function tests, as suggested by the American Academy of Physical Medicine and Rehabilitation 4, 5, 8
• If routine blood glucose testing is normal, consider testing for impaired glucose tolerance in patients with distal symmetric sensory polyneuropathy, as recommended by the American Academy of Physical Medicine and Rehabilitation 5

Special Considerations for Specific Polyneuropathy Types

Small Fiber Polyneuropathy

• When small fiber polyneuropathy is suspected, skin biopsy with intraepidermal nerve fiber density measurement is recommended, as suggested by the European Federation of Neurological Societies 6, 7

Autonomic Neuropathy

• For suspected autonomic involvement, perform autonomic testing including heart rate variability to deep breathing and Valsalva maneuver, as recommended by the American Autonomic Society 7, 9

Hereditary Neuropathy

• Consider genetic testing when a patient exhibits a hereditary neuropathy phenotype, has a family history of neuropathy, or initial genetic testing should focus on CMT1A duplication/HNPP deletion, Cx32 (GJB1), and MFN2 mutations, as suggested by the American Academy of Physical Medicine and Rehabilitation 5

Streamlining the Diagnostic Approach

• Cerebrospinal fluid analysis has low diagnostic yield except in suspected demyelinating polyneuropathies, as noted by the American Academy of Physical Medicine and Rehabilitation 4
• Nerve biopsy should be reserved for cases where vasculitis or other specific inflammatory conditions are suspected, as recommended by the European Federation of Neurological Societies 6

Common Pitfalls to Avoid

• Relying solely on laboratory tests without clinical correlation, as laboratory tests alone have only a 37% diagnostic yield, as noted by the American Academy of Physical Medicine and Rehabilitation 4
• Failing to test for B12 deficiency with metabolites, as serum B12 levels in the low-normal range may still indicate deficiency, as suggested by the American Academy of Physical Medicine and Rehabilitation 8
• Overlooking impaired glucose tolerance in patients with normal fasting blood glucose, as recommended by the American Academy of Physical Medicine and Rehabilitation 5
• Performing autonomic testing during acute illness, stressful conditions, or without appropriate medication washout, as noted by the American Autonomic Society 9